Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive
and fatal neurodegenerative disease that leads to a loss of muscle control due to nerve cells …

Abstract Background and Objective The efficacy and safety of edaravone for the treatment of
amyotrophic lateral sclerosis (ALS) remain unclear. The aim of this meta-analysis was to …

The etiology of amyotrophic lateral sclerosis (ALS) is unknown. Oxidative stress may be one
of the major mechanisms involved. In vitro and in vivo data of edaravone suggest that it may …

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative
disease. Although the pathogenesis remains unresolved, oxidative stress is known to play a …

Background and purpose Oxidative stress has been implicated in the pathogenesis of
amyotrophic lateral sclerosis (ALS). Edaravone, a free radical scavenger, was approved as …

Abstract Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24‐week edaravone vs …

Background Based on the results of randomized, double-blind, placebo-controlled trials, the
benefit and safety of edaravone in the treatment of amyotrophic lateral sclerosis remain …

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal
degenerative disease that affects the motor neurons connecting the brain and spinal cord …

Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral
sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week …